Envestnet Portfolio Solutions Inc. Makes New $571,000 Investment in Hims & Hers Health, Inc. $HIMS

Envestnet Portfolio Solutions Inc. bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,451 shares of the company’s stock, valued at approximately $571,000.

A number of other hedge funds also recently bought and sold shares of the stock. Northern Trust Corp lifted its holdings in Hims & Hers Health by 19.5% during the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock worth $71,969,000 after buying an additional 397,310 shares during the period. Yong Rong HK Asset Management Ltd lifted its holdings in Hims & Hers Health by 41.2% during the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock worth $70,920,000 after buying an additional 700,100 shares during the period. Nuveen LLC purchased a new stake in Hims & Hers Health during the first quarter worth $58,403,000. BIT Capital GmbH lifted its holdings in Hims & Hers Health by 7.4% during the first quarter. BIT Capital GmbH now owns 1,642,493 shares of the company’s stock worth $48,536,000 after buying an additional 112,949 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Hims & Hers Health by 1.2% during the first quarter. Bank of New York Mellon Corp now owns 1,260,292 shares of the company’s stock worth $37,242,000 after buying an additional 15,339 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $49.40 on Wednesday. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The business has a 50-day simple moving average of $51.07 and a two-hundred day simple moving average of $49.21. Hims & Hers Health, Inc. has a fifty-two week low of $18.33 and a fifty-two week high of $72.98. The company has a market cap of $11.17 billion, a PE ratio of 61.75, a P/E/G ratio of 3.50 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same period in the previous year, the company earned $0.06 earnings per share. Hims & Hers Health’s revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, insider Michael Chi sold 13,749 shares of the company’s stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $694,324.50. Following the transaction, the insider directly owned 297,139 shares of the company’s stock, valued at $15,005,519.50. This represents a 4.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 145,000 shares of the company’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00. Following the completion of the transaction, the chief financial officer directly owned 128,984 shares in the company, valued at approximately $7,139,264.40. The trade was a 52.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,434,306 shares of company stock valued at $74,369,240 in the last quarter. Insiders own 17.71% of the company’s stock.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of analyst reports. Canaccord Genuity Group restated a “buy” rating and set a $68.00 target price on shares of Hims & Hers Health in a report on Friday, September 12th. KeyCorp initiated coverage on Hims & Hers Health in a report on Tuesday. They set a “sector weight” rating for the company. Zacks Research lowered Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Truist Financial decreased their price objective on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a report on Monday, August 18th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Two research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.